These technologies make critical data about protocols, patients, enrollment, investigators, treatment results and trial progress available to all members of the project team inclusive of project managers, monitors, data managers, operations, and finance.

Protocol Manager and AdWATCH will allow us to improve team communications, integrate our operations and manage trial data more efficiently for our clients." said Bonnie Neuhardt, Averion’s Chief Information Officer. “This investment reinforces Averion’s commitment to providing our clients with decision making and oversight tools for hastening product development times”.

We are committed to our clients and employees to offer the latest technology innovations to improve the product development process for our clients." commented, Dr. Philip Lavin, Averion President and CEO.

Protocol Manager and AdWatch are proprietary software systems developed and supported by WBS. Protocol Manager increases the efficiency of communications between parties involved in clinical trials by allowing access to global clinical trial data electronically, eliminating the need to transcribe, mail and fax traditional paper forms. AdWatch insures patient safety by automatically collecting adverse events from patient data in Protocol Manager and alerting professional monitors when adverse events occur. AdWatch then populates the MedWatch forms with the information required by government regulatory agencies and electronically transmits the forms to the FDA.

“We are pleased to be a part of the product development process,” said Michael Regentz, Winchester's Managing Director. “Winchester has the business knowledge and is committed to insure success of this effort to streamline clinical trials management.”